Abalone Bio
Abalone Bio is tackling challenging undrugged targets underlying diseases affecting millions, focusing first cell-specific antibody drugs to treat obesity and metabolic disease without the GI side effects that cause 25% of GLP-1 drug patients to quit after 1 year. + High throughput experimental measurement uniquely leverages AI/ML: We’ve engineered cells to measure antibodies for pharmacological activity, not just structure or binding like others, 100 million at a time, 100X+ the throughput of o
Y Combinator
yc-company-directory #4316Abalone Bio is tackling challenging undrugged targets underlying diseases affecting millions, focusing first cell-specific antibody drugs to treat obesity and metabolic disease without the GI side effects that cause 25% of GLP-1 drug patients to quit after 1 year. + High throughput experimental measurement uniquely leverages AI/ML: We’ve engineered cells to measure antibodies for pharmacological activity, not just structure or binding like others, 100 million at a time, 100X+ the throughput of o
sourceAbalone Bio is classified as AI infrastructure from source descriptions and fund-directory context. Similar companies below are ranked from offline product facets and meaningful description overlap; category and source affiliation can only strengthen an existing product match. For lookup-created rows, the profile starts as pending enrichment until deeper source collection runs.
Local clusters rerank extracted product concepts and description terms. The generated graph remains the fallback for sparse descriptions: offline reciprocal product-similarity graph: extracted concepts + description terms + bounded category/affiliation boosts. Minimum fallback score: 0; max competitors: 6.
Companies similar to Abalone Bio
A deterministic local cluster built from offline product facets and meaningful description terms. Category and selected-institution affiliation provide bounded tie-breaks. Open any peer to continue exploring its cluster.
Eugit Therapeutics
match 81Eugit Therapeutics targets the issue of non-specific drugs that cause toxicity and clinical trial failures, affecting millions with tissue-specific inflammatory diseases. TAGHOME delivers drugs with precision to diseased tissues using T cell receptors, enhancing safety and improving efficacy. Our initial focus is on the 3.1 million U.S. individuals with Inflammatory Bowel Disease, aiming to initiate clinical trials within two years. Cofounded by George Church (Harvard) and funded by Y Combinator
shared product terms: target, disease, affect, million; shared product theme: health and clinical care; same category: AI infrastructure; shared affiliation: Y Combinator
Olio Labs
match 73Olio labs uses AI to develop combination therapeutics that consider the thousands of interacting proteins in your body rather than targeting just one or two. Their lead combinations target obesity and are more effective with fewer side effects than Ozempic, the fastest growing drug of all time. Their custom ML built from real-world expertise and cutting edge AI searches trillions of combinations to find the perfect one.
shared product terms: target, drug, obesity, side; shared product theme: health and clinical care; same category: AI infrastructure; shared affiliation: Y Combinator
Volt Health
match 70Volt is an electrostimulation wearable to treat diseases like incontinence. The founder has already taken six medical devices to market, including the Cool Sculpting device that sold for billions. Incontinence affects 25 million people and is a $25 billion market. The device stimulates the muscles to get them the give feedback to receptors. This helps those suffering from incontinence to not pee when they don’t want to. The device can also target other conditions like migraines and comes with pr
shared product terms: target, disease, affect, million; shared product theme: health and clinical care; shared affiliation: Y Combinator
Arpeggio Bio
match 68Arpeggio Bio is a pioneering pharmaceutical company that develops drugs targeting transcription factors using AI and high-throughput RNA-sequencing. With $20M in venture funding, we've targeted "undruggable" proteins like NRF2, TEAD, and GPX4 where our lead program is rapidly progressing towards a DC for the treatment of IO-resistant melanoma. With partnerships with J&J and FORMA, we've validated our platform in rare disease and inflammation with a significant Phase I success.
shared product terms: bio, target, disease, drug; same category: AI infrastructure; shared affiliation: Y Combinator
Bodyport
match 62Bodyport’s cardiovascular sensing weight scale and predictive algorithms detect early changes in cardiac function to help prevent avoidable hospitalizations. Bodyport is initially targeting heart failure, a chronic condition affecting over 6M Americans and a leading cause of hospitalizations (1M/year) and healthcare spending ($35B/year). Bodyport’s novel scale measures cardiac output, congestion, heart rate, and other leading indicators of cardiovascular health — all in the same step patients al
shared product terms: target, affect, cause, patient; shared product theme: health and clinical care; shared affiliation: Y Combinator
UBI Meat Experts in Quality Assurance
match 47UBI's a meat grading and monitoring platform that leverages AI/ML helping meat processors to measure and document quality assurance in real-time.
shared extracted concepts: ai ml; shared product terms: leverage, ml, measure, time; same category: AI infrastructure